Cyclic Citrullinated Peptide Antibodies, IgG, Serum
Use
This test is useful for evaluating patients suspected of having rheumatoid arthritis (RA) and for differentiating RA from other inflammatory arthritis or connective tissue diseases. The presence of cyclic citrullinated peptide (CCP) antibodies is suggestive of RA, especially when clinical features of the disease are present. High levels of CCP antibodies can identify RA patients with erosive joint disease.
Special Instructions
Not provided.
Limitations
Positive results for CCP antibodies may occur in some patients with systemic lupus erythematosus or other autoimmune, connective tissue diseases. Antirheumatic therapy should not be initiated based solely on a positive CCP antibody test, and changes in treatment should not be based upon CCP antibody levels. In some subgroups, there is a 10% false-positive rate. Late diagnosis may lead to increased morbidity and mortality, emphasizing the importance of early testing and diagnosis.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Cyclic Citrullinated Peptide Antibodies
Analyte
LOINC Codes
- 33935-8 - cCP IgG SerPl-aCnc
- 33935-8 - cCP IgG SerPl-aCnc
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Preferred collection container is Serum gel. Acceptable alternative is Red top. Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimen will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |